Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients
Launched by TEHRAN UNIVERSITY OF MEDICAL SCIENCES · Nov 17, 2009
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnose of Acute lymphoblastic leukemia
- • Age between 16 to 50 year
- • New case of ALL
- Exclusion Criteria:
- • Primary CNS involvement
- • Primary Testis involvement
- • Previously treated
About Tehran University Of Medical Sciences
Tehran University of Medical Sciences (TUMS) is a prestigious institution dedicated to advancing healthcare through innovative research and education. As a leading clinical trial sponsor, TUMS is committed to conducting high-quality, ethically sound clinical research that contributes to the understanding and treatment of various medical conditions. With a strong emphasis on collaboration and interdisciplinary approaches, TUMS harnesses the expertise of its diverse faculty and state-of-the-art facilities to facilitate groundbreaking studies that aim to improve patient outcomes and enhance public health. Through its rigorous oversight and adherence to regulatory standards, TUMS ensures the integrity and reliability of its clinical trials, fostering trust and transparency in the research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Ardeshir Ghavamzadeh, MD
Study Chair
Hematology-Oncology and SCT Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials